Regeneron Reports First Quarter 2017 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Regeneron Pharma (REGN) PT Raised to $475 at Cowen
May 4, 2017 3:39 PM EDTCowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $475.00 (from $380.00) while maintaining a Market Perform rating following Q1 results.
Analyst Phil Nadeau is updating estimates to reflect Dupixent's fast start, Eylea's deceleration.
FY 2017 EPS goes from $12.25 to $1.25 and FY 2018 EPS goes from $14.90 to $13.20.
... MoreRegeneron (REGN) Misses Q1 EPS by 15c, Offers FY Guidance
May 4, 2017 6:40 AM EDTRegeneron (NASDAQ: REGN) reported Q1 EPS of $2.92, $0.15 worse than the analyst estimate of $3.07. Revenue for the quarter came in at $1.32 billion versus the consensus estimate of $1.3... More
